We are live on ! Find out more
TCM

Tang Capital Management Portfolio holdings

AUM $1.97B
1-Year Est. Return 125.1%
This Fund
S&P 500
This Quarter Est. Return
+49.88%
1 Year Est. Return
+125.1%
3 Year Est. Return
+474.48%
5 Year Est. Return
+595.08%
10 Year Est. Return
+2,831.44%
AUM
$1.03B
AUM Growth
+$316M
Cap. Flow
+$4.54M
Cap. Flow %
0.44%
Top 10 Hldgs %
93.6%
Holding
27
New
2
Increased
4
Reduced
7
Closed
6

Top Buys

Rank Stock Value
1
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$52.2M
2
PBYI icon
Puma Biotechnology
PBYI
+$5.85M
3
ANAB icon
AnaptysBio
ANAB
+$4.35M
4
LJPC
La Jolla Pharmaceutical Company
LJPC
+$3.75M
5
CHRS icon
Coherus Oncology
CHRS
+$3.39M

Top Sells

Rank Stock Value
1
RLMD icon
Relmada Therapeutics
RLMD
+$33.8M
2
EOLS icon
Evolus
EOLS
+$13.7M
3
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$4.21M
4
TECX
Tectonic Therapeutic
TECX
+$3.43M
5
RDUS
Radius Health, Inc.
RDUS
+$2.49M

Sector Composition

Rank Sector Weight
1 Healthcare 99.31%
2 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ITCI
26
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-41,444
Closed -$637K
GTHX
27
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
– –
-170,000
Closed -$1.87M
1
2

Similar funds

HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BC
Blackhill Capital Morristown, New Jersey $1.94B AUM 18.09% 1-Year Est. Return
FFH
Fairfax Financial Holdings Toronto, Ontario, Canada $1.94B AUM 27.76% 1-Year Est. Return

Tang Capital Management's Q2 2020 Portfolio in Review

As of Q2 2020, Tang Capital Management held 27 positions worth $1.03B, up 44% from $712M the previous quarter. Its ten largest holdings account for 94% of the portfolio.

Tang Capital Management's Q2 2020 filing shows 2 new, 4 increased, 7 reduced and 6 closed positions. Its largest new stake was Biohaven Pharmaceutical Holding Company Ltd.: 980,461 shares worth $71.7M. The largest sale was Relmada Therapeutics, an estimated $33.8M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Industrials.

  • Tang Capital Management's largest Q2 2020 buy was Biohaven Pharmaceutical Holding Company Ltd.: 980,461 shares worth $71.7M.
  • Tang Capital Management added most to Puma Biotechnology in Q2 2020, an estimated $5.85M increase.
  • Tang Capital Management's biggest Q2 2020 reduction was Relmada Therapeutics, cutting an estimated $33.8M.
  • Tang Capital Management fully exited Evolus in Q2 2020, selling an estimated $13.7M.
  • Tang Capital Management's ten largest holdings make up 94% of its $1.03B portfolio in Q2 2020.
  • Tang Capital Management opened 2 new positions and closed 6 in Q2 2020.
  • Tang Capital Management's portfolio value rose 44% quarter-over-quarter to $1.03B.

Based on Tang Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.